An FDA Panel Just Backed BPC-157 and KPV by One Vote. Here's What That Actually Means.

What happened

On Thursday, July 23, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend that BPC-157 and KPV be added to the 503A Bulks List. That's the FDA's list of substances a state-licensed compounding pharmacy is allowed to use when it prepares a medication for an individual patient. BPC-157 was under consideration for ulcerative colitis, KPV for wound treatment and inflammatory conditions.

The committee met over two days at FDA headquarters in Maryland, worked through seven peptides, and by Friday afternoon had voted in favor of six of them.

If you follow this space at all, you've probably seen the word "approved" attached to this story somewhere. It doesn't belong there. This was an advisory vote, it isn't binding, and the FDA hasn't decided anything yet.

The part most coverage is blurring

An advisory committee gives the FDA advice. That's the whole job. The agency picks the panel, asks it questions, listens to the vote, then makes its own decision, and it's free to disagree.

FDA's own scientists said no

This is the detail that makes the vote unusual. In the scientific review it posted before the meeting, FDA staff recommended against adding these peptides to the 503A Bulks List, citing safety and efficacy concerns. On BPC-157 specifically, the briefing package said there's a "lack of evidence to support the effectiveness of BPC-157 (free base) and BPC-157 acetate as a treatment for ulcerative colitis."

There was also a more basic problem raised in the room, and it's worth sitting with. FDA's Russell Wesdyk asked, plainly, "What is BPC-157?" He noted that some people believe it's one amino acid sequence and others disagree, and said the agency can't establish quality standards until more is known about the substance. FDA's Mai Tu agreed that the peptide is "not well-characterized."

Read that again if you buy research peptides, because it's the most useful line in the whole meeting. The regulator is saying it isn't confident it knows exactly what this compound is. That's an identity and manufacturing question, and it sits underneath every purity claim anyone makes about this molecule.

The briefing materials also noted three adverse event reports received after BPC-157 injection, including a 55-year-old woman with nine days of redness and swelling at the injection site, and a 28-year-old man who went to the emergency room with shortness of breath. FDA was careful to say it's unclear whether BPC-157 caused either one, since these reports come with limited information and other medications in play.

The panel was genuinely split

Eight to six with an abstention is about as close as these votes get, and the disagreement went on the record.

Committee member Elizabeth Rebello, a professor of anesthesiology and perioperative medicine at the University of Texas MD Anderson Cancer Center, pointed to the "lack of efficacy data and randomized controlled trials" for these compounds. Bill Zamboni, a pharmacologist at the University of North Carolina, said, "There are too many unknowns about this product."

On the other side, David Pope of XiFin Pharmacy Solutions said, "I voted yes because it's time to put this decision back in the hands of the physician and pharmacist."

Both positions are coherent, which is why the vote was so close. One says the data isn't there yet. The other says the data will never be there for an off-patent peptide nobody's going to fund trials for, so let a prescriber and a pharmacist make the call.

How the rest of the meeting went

Emideltide was the only one that didn't make it, and it failed by a single vote. Committee member Kevin Zacharoff, an anesthesiologist and clinical assistant professor at Stony Brook University's Renaissance School of Medicine, explained his no vote this way. "As a clinician, it's impossible for me not to take FDA's recommendations to heart with respect to safety and efficacy."

The politics in the room

You can't tell this story honestly without the context around the panel itself. Health and Human Services Secretary Robert F. Kennedy Jr. has publicly called himself a "big fan" of peptides and has said he'd work to overturn the current restrictions. In June, the FDA added eight new members to the committee, many with reported ties to prescribing or promoting peptides. Those apparent conflicts were covered by multiple outlets and were reportedly a concern among some FDA staff. Shortly before the meeting the agency added several more temporary voting members with academic, clinical research, and pain and substance use backgrounds.

None of that makes the vote invalid. Advisory panels get built from people who know a field, and knowing a field usually means having worked in it. But when the agency's own scientists recommend caution and the panel votes the other way by one seat, how the panel was assembled is part of the story.

What this means for you right now

Practically, nothing changed this week.

If you buy peptides labeled for research use, this vote doesn't touch that market. A recommendation about the 503A Bulks List doesn't alter the status of research-use products one way or the other. Price and vendor quality are still the variables you actually control, and they're still all over the map, which is what our price comparison tool and the vendor directory are for.

If you've been hoping BPC-157 or KPV would become available through a compounding pharmacy with a prescription, this is a real step in that direction, and it's only a step. The FDA still has to decide whether to accept the recommendation, and formally adding a substance to the list runs through notice-and-comment rulemaking, which takes many months. Anyone telling you today that these peptides are now legal, cleared, or FDA-backed is getting ahead of the facts.

Next thing worth watching is whether the FDA signals agreement or disagreement with the committee, and whether any formal rulemaking opens on these substances. We'll cover it here when it happens.